Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06045026 · ClinicalTrials.gov registry record · NA

A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management

A NA study, sponsored by HALEON.

Completed
Registry status
NA
Development phase
536
Enrollment target

NCT06045026: Completed NA study, sponsored by HALEON.

NCT06045026 is a NA study that has completed, run by HALEON. The registered enrollment target is 536 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06045026, a NA study, has completed, sponsored by HALEON.

COMPLETED
Registry status
NA
Development phase
536 participants
Enrollment target

Study Summary

This study will evaluate the impact of long-term use of a desensitizing toothpaste containing 0.454 percent (%) stannous fluoride (SnF2) on oral health related quality of life (OHrQoL) in a population of self-reported dentin hypersensitivity (DH) sufferers. Data generated will provide real world information on the DH experience and DH management with a daily use anti-sensitivity treatment.

Primary Outcome

The DHEQ is a condition-specific measure of oral-health related quality-of-life (OHrQoL) in relation to dentin hypersensitivity (DH). Section 2 of DHEQ included 34 questions grouped into 5 separate domains: Restrictions(Q1-4), Adaptation(Q5-16), Social Impact(Q17-21), Emotional Impact(Q22-29), and Identity(Q30-34). Participants scored each question using a 7-point scale ranging from 1 to 7 where 1=strongly disagree, 2=disagree, 3=disagree a little, 4=neither agree nor disagree, 5=agree a little,

Interventions

  • OTHER Stannous fluoride

Trial Details

FieldValue
Enrollment Target 536 participants
Start Date 2023-09-21
Est. Completion 2024-04-25
Phase NA
HALEON

34 total trials

What the finished NCT06045026 record still lists

NCT06045026 is an interventional study that assigns participants to a tested intervention. The registered 536 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 1 intervention - of which Stannous fluoride is the first listed.

NCT06045026 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06045026 about?

NCT06045026 is a clinical study titled "A Real-World Evidence Study Evaluating Oral Health Related Quality Of Life With Use Of A Stannous Fluoride Anti-Sensitivity Toothpaste For Dentin Hypersensitivity Management". This study will evaluate the impact of long-term use of a desensitizing toothpaste containing 0.454 percent (%) stannous fluoride (SnF2) on oral health related quality of life (OHrQoL) in a population of self-reported dentin hypersensitivity (DH) sufferers. Data generated will provide real world inf...

What is the current status of trial NCT06045026?

This trial is currently completed. It is a NA study. The enrollment target is 536 participants. The study started on 2023-09-21. Estimated completion is 2024-04-25.

What interventions are being tested in trial NCT06045026?

The interventions under investigation include: Stannous fluoride (OTHER).

Who is sponsoring clinical trial NCT06045026?

This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06045026's enrollment target sits among peer trials

536 188th of 2000 higher than 1,813 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05880004 · 537 participants · NA

    Developing a Support Application for Food Pantries (SAFPAS) to Improve Client Access to Healthy Foods & Enhance Emergency Preparedness

  • NCT05614739 · 535 participants · Phase 1

    FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

  • NCT07091617 · 535 participants · NA

    Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

  • NCT03772028 · 538 participants · Phase 3

    Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06045026, the US trial registry maintained by the National Library of Medicine. NCT06045026 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.